Rice’s Biotech Launch Pad To Lead Commercialization Of Implant Treatment For Diabetes, Obesity 

The federal Advanced Research Projects Agency for Health (ARPA-H) recently awarded researchers from Rice University and colleagues up to $34.9 million toward the development of a bioelectronic implant designed to improve adherence for obesity and type 2 diabetes (T2D) treatment. The funding will be used to cover development and manufacturing costs.

The device, “Rx On-site Generation Using Electronics” (ROGUE), is a self-contained, durable implantable device that houses cells engineered to produce T2D and obesity therapies in response to an individual’s physiological needs. Rice University’s Biotech Launch Pad will lead the ROGUE commercialization effort. . . .